Rimonabant pharmacokinetics in healthy and obese subjects.

被引：13
|
作者：
Turpault, S [1 ]
Kanamaluru, V [1 ]
Lockwood, GF [1 ]
Bonnet, D [1 ]
Newton, J [1 ]
机构：
[1] Sanofi Aventis, Malvern, PA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2006年 / 79卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2005.12.177
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P50 / P50
页数：1
相关论文
共 50 条
  • [41] Sex-based pharmacokinetics of intravenous levofloxacin (LEV) in healthy subjects.
    Overholser, BR
    Kays, MB
    Lagvankar, S
    Goldman, M
    Sowinski, KM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P66 - P66
  • [42] THE EFFECT OF EVEROLIMUS (EVE) ON THE PHARMACOKINETICS (PK) OF MIDAZOLAM (MID) IN HEALTHY SUBJECTS.
    Urva, S.
    Bouillaud, E.
    Delaney, R.
    Jappe, A.
    Cheung, W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S128 - S128
  • [43] Tegaserod does not significantly affect the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Ledford, P
    On, N
    Ligueros-Saylan, M
    Campestrini, J
    Osborne, S
    GASTROENTEROLOGY, 2000, 118 (04) : A1184 - A1184
  • [44] LY451395 cerebrospinal fluid pharmacokinetics in healthy human subjects.
    Jhee, S
    Chalon, S
    Toublanc, N
    Brandt, J
    Chappell, A
    Shiovitz, TS
    Farrar, S
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (09): : 1067 - 1067
  • [45] Cerebrospinal fluid pharmacokinetics of LY450108 in healthy human subjects.
    Jhee, SS
    Chalon, S
    Cleton, A
    Brandt, JE
    Chappell, AS
    Francisco, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P8 - P8
  • [46] Tolerability and pharmacokinetics of fixed doses of buspirone administered transdermally to healthy subjects.
    Fulmor, IE
    Szylleyko, OJ
    Kollia, GD
    Ford, NF
    Salazar, DE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 167 - 167
  • [47] PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY, AND SAFETY OF BMS-938790 IN HEALTHY SUBJECTS.
    Lee, S.
    Minnich, A.
    Desai, D. D.
    Shen, Y.
    Tang, H.
    Postelnek, J.
    Trigona, W. L.
    Townsend, R.
    Murthy, B.
    Parsons, R. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S84 - S84
  • [48] Pharmacokinetics and dose proportionality of tazarotene following oral administration in healthy subjects.
    Lee, E
    Borbridge, LM
    Walker, P
    Suri, A
    Tang-Liu, DDS
    Yu, DK
    PHARMACOTHERAPY, 2002, 22 (10): : 1364 - 1364
  • [49] The effect of pioglitazone on carotid artery intimal thickness in healthy obese subjects.
    Salehian, B
    Bilas, J
    Lee, T
    Dwyer, J
    JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (01) : S92 - S92
  • [50] Pharmacokinetics, pharmacodynamics, and safety of YM905 in healthy, elderly subjects.
    Smulders, RA
    Krauwinkel, W
    van Zijtveld, J
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (04) : S101 - S102
12345